Cargando…

PS99. First episode depression and monotherapy with escitalopram: A 16-week, open-label, flexible-dose study

Detalles Bibliográficos
Autores principales:	Ravindran, Arun V., Harkness, Kate, Ravindran, Lakshmi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616696/ http://dx.doi.org/10.1093/ijnp/pyw043.099

Ejemplares similares

PS176. A functional resonance imaging investigation of escitalopram monotherapy in first episode depression
por: Ravindran, Arun V., et al.
Publicado: (2016)

PS100. Open-label Desvenlafaxine as Monotherapy for Persistent Depression Disorder: A Pilot Study
por: Ravindran, Arun V., et al.
Publicado: (2016)

PS108. Characteristics of escitalopram discontinuation syndrome
por: Norio-Furukori, Yasui, et al.
Publicado: (2016)

Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex
por: Tian, Shui, et al.
Publicado: (2019)

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang, Gang, et al.
Publicado: (2018)

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
por: Jiang, Kaida, et al.
Publicado: (2017)

A pilot study on improvements in attention function in major depressive disorder after 12 weeks of escitalopram monotherapy or combined treatment with agomelatine
por: Li, Zhe, et al.
Publicado: (2023)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

PS85. Efficacy and Safety of Generic Escitalopram (Lexacure) in Patients with Major Depressive Disorder: A 6-week, Multi-center, Randomized, Rater-blinded, Escitalopram-comparative, Non-inferiority Study
por: Jeong, Jong-Hyun, et al.
Publicado: (2016)

Efficacy of Buspirone Augmentation of Escitalopram in Patients with Major Depressive Disorder with and without Atypical Features: A Randomized, 8 Week, Multicenter, Open-Label Clinical Trial
por: Shin, Cheolmin, et al.
Publicado: (2020)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Escitalopram-induced extrapyramidal symptoms
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2019)

A 12-week Comparative Prospective Open-label Randomized Controlled Study in Depression Patients Treated with Vilazodone and Escitalopram in a Tertiary Care Hospital in North India
por: Bathla, Manish, et al.
Publicado: (2018)

PS210. Effect of Desvenlafaxine on Altered Heart Rate Variability in Persistent Depressive Disorder
por: Ravindran, Arun V., et al.
Publicado: (2016)

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
por: Maity, Nabakumar, et al.
Publicado: (2014)

Manic Episode as a Result of Adding Trazodone to a Patient under Escitalopram Treatment
por: İzci, Filiz, et al.
Publicado: (2021)

Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy
por: Espinola, Caroline W., et al.
Publicado: (2022)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
por: Kim, Nam Hoon, et al.
Publicado: (2017)

Agomelatine as monotherapy for major depression: an outpatient, open-label study
por: Pecenak, Jan, et al.
Publicado: (2013)

The XyloTron: Flexible, Open-Source, Image-Based Macroscopic Field Identification of Wood Products
por: Ravindran, Prabu, et al.
Publicado: (2020)

Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial
por: Choi, Kwan-Woo, et al.
Publicado: (2012)

Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials
por: Li, Guanjun, et al.
Publicado: (2017)

Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial
por: Kang, Nam-In, et al.
Publicado: (2016)

Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]
Publicado: (2013)

One‐week escitalopram intake alters the excitation–inhibition balance in the healthy female brain
por: Zsido, Rachel G., et al.
Publicado: (2022)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial
por: Mahajan, Sonia Shinde, et al.
Publicado: (2019)

Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
por: MACHADO-VIEIRA, RODRIGO, et al.
Publicado: (2014)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial
por: Ohsawa, Yutaka, et al.
Publicado: (2019)

Escitalopram induced mania
por: Parker, Shubangi, et al.
Publicado: (2007)

Escitalopram in patients with psoriasis
por: Artemieva, M., et al.
Publicado: (2021)

Escitalopram Induced Angioedema
por: Conde, Samantha L, et al.
Publicado: (2022)

Comparative Analysis of the Effects of Escitalopram, Pramipexole, and Transcranial Magnetic Stimulation on Depression in Patients With Parkinson Disease: An Open-Label Randomized Controlled Trial
por: Chen, Jing, et al.
Publicado: (2022)

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension
por: Pittock, Sean J, et al.
Publicado: (2021)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Yang, Sae Jeong, et al.
Publicado: (2021)

PS91. The effects of fluvoxamine on the steady-state plasma concentrations of escitalopram and desmethylescitalopram in depressed Japanese patients.
por: Kubo, Kazutoshi, et al.
Publicado: (2016)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
por: Landy, Stephen, et al.
Publicado: (2018)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

List of PS documents reproduced during the week May 16 - 20, 1960
por: CERN. Geneva. Proton Synchrotron Division
Publicado: (1960)

Cannot write session to /tmp/vufind_sessions/sess_1uiea9nvr7htr0mg7lv9j76fsf